Evidence map›Paper›PMID 40099972›Full record

ArticleCancer research communications2025

Osteosarcoma Exosome Priming of Primary Human Lung Fibroblasts Induces an Immune Modulatory and Protumorigenic Phenotype.

Eric P Palmer, Kathryn E Cronise, Laurel A Haines, Sunetra Das, Aaron Offermann, Carina P Easton, Daniel P Regan

Abstract read
In one paragraph

Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eric P PalmerFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado.ORCID 0009-0009-5217-1403
Kathryn E CroniseFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado.ORCID 0000-0003-3224-1469
Laurel A HainesFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado.ORCID 0000-0002-8410-248X
Sunetra DasFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado.ORCID 0000-0002-8941-1468
Aaron OffermannFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado.ORCID 0009-0004-0441-4822
Carina P EastonFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado.ORCID 0000-0001-6689-8560
Daniel P ReganFlint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado.ORCID 0000-0002-3148-1332

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Dual-Degree Medical Scientist Training Program for VeterinariansT32GM136628 · NIGMS · COLORADO STATE UNIVERSITY · PI ANNE C AVERY, Daniel Patrick Regan · 2020 to 2026
$1.9M
Elucidating the role and regulation of periostin in therapy-induced chemoresistance in metastatic breast cancerK01OD022982 · OD · COLORADO STATE UNIVERSITY · PI REGAN, DANIEL PATRICK · 2016 to 2021
$720k
Alveolar Macrophages as Sentinels of Osteosarcoma Pulmonary Micro-MetastasisR03OD028265 · OD · COLORADO STATE UNIVERSITY · PI REGAN, DANIEL PATRICK · 2020 to 2021
$228k
NCI NIH HHS P30 CA046934NIGMS NIH HHS T32 GM136628NIH HHS K01 OD022982NIH HHS R03 OD028265
6 · The paper itself

Abstract

abstractOsteosarcoma (OS) is the most common malignant bone cancer. Thirty to forty percent of all patients with OS develop tumor recurrence, almost exclusively in the form of lung metastasis, which is associated with a dismal 20% 5-year survival rate. Cancer-associated fibroblasts are a critical cell type within the lung tumor microenvironment that promote immune suppression, drug resistance, and tumor cell survival. Prior work shows tumor cells can co-opt fibroblasts to a protumorigenic phenotype via exosome-mediated intercellular communication. Currently, the mechanisms by which OS exosomes modulate resident lung fibroblast (LF) function have not been evaluated. To investigate this, we isolated exosomes from a panel of six OS cell lines. We assessed the uptake and response of human donor–derived primary LFs (n = 4) to OS exosome treatment in vitro via flow cytometry, confocal fluorescent microscopy, proliferation assays, phosphokinase array, multiplex cytokine analysis, and RNA sequencing. We observed that LFs efficiently take up OS exosomes, which are associated with the induction of MAPK pathway activation, fibroblast proliferation, and significantly enhanced secretion of IL-6, CXCL8, and CCL2 compared with untreated LFs. RNA sequencing of exosome-treated LFs confirmed these responses and revealed significant enrichment of pathways related to cytokine secretion, proliferation, immune cell chemotaxis, migration, proinflammatory, and profibrotic mediators. Finally, in an exosome-educated LF–OS coculture model, exosome-educated LFs conferred significantly increased OS cell survival and proliferation compared with untreated fibroblasts. Together, these data suggest that the OS-derived exosomes can induce a hallmark cancer-associated fibroblast–like inflammatory phenotype in LFs, providing valuable insights into mechanisms that may promote recurrent OS lung metastasis. SIGNIFICANCE: These findings provide a critical first step in characterizing the capacity of OS-derived exosomes to reprogram primary LFs toward a tumor-promoting inflammatory phenotype in vitro, offering novel molecular targets for the modulation of fibroblasts in the lung microenvironment as potential therapeutic strategies to prevent OS metastasis.

Indexed as

Bone NeoplasmsExosomesFibroblastsLungOsteosarcomaHumansLung NeoplasmsPhenotypeTumor Microenvironment

Identifiers

PMID40099972
PMCPMC11987067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.